Key result
Ticagrelor provides a safe antiplatelet alternative following clopidogrel-induced severe neutropenia after coronary stenting.
Why the study?
Is ticagrelor a safe alternative in patients with clopidogrel-associated neutropenia after coronary stenting?
Case Report (n=1)
Is ticagrelor a safe alternative in patients with clopidogrel-associated neutropenia after coronary stenting?
Ticagrelor may be a safe alternative P2Y12 inhibitor for patients who develop clopidogrel-induced neutropenia after coronary stenting.
Answers are grounded in this paper and cite their sources.
May be considered in clopidogrel-induced neutropenia; single case leaves open need for prospective confirmation.
Aspirin in combination with platelet P2Y12 receptor blocker has become the mainstay antiplatelet treatment strategy for the prevention of stent thrombosis. Ticlopidine was the first widely used P2Y12 receptor blockers, but clopidogrel has mostly replaced the use of ticlopidine due to its more favorable adverse event profile on bone marrow. However, when clopidogrel induced bone marrow toxicity occurs, little is known about the efficacy and safety of alternative treatments, and thus, in these cases, medical decisions may be very difficult. We report a case of clopidogrel-induced severe neutropenia in a patient treated with coronary stent and safety of alternative treatment with ticagrelor.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2014) conducted a case report in Clopidogrel-induced severe neutropenia (n=1). Ticagrelor was evaluated on Safety of alternative treatment with ticagrelor. Ticagrelor was safely used as an alternative antiplatelet treatment in a patient who developed severe neutropenia induced by clopidogrel after coronary stenting.
Synapse has enriched 10 related papers. Consider them for comparative context: